Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 2241-2248 |
| Number of pages | 8 |
| Journal | Haematologica |
| Volume | 104 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - 2019 |
Keywords
- cyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine
- immunoglobulin
- lactate dehydrogenase
- rituximab
- acute leukemia
- adult
- anaphylaxis
- Article
- autograft
- autologous hematopoietic stem cell transplantation
- cancer growth
- cancer immunotherapy
- cancer staging
- cancer survival
- controlled study
- disease exacerbation
- disease free survival
- female
- follicular lymphoma
- Follicular Lymphoma International Prognostic Index
- follow up
- human
- male
- middle aged
- minimal residual disease
- multicenter study
- myelodysplastic syndrome
- overall survival
- polymerase chain reaction
- prospective study
- randomized controlled trial
- remission
- sudden death
Fingerprint Dive into the research topics of 'Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial'. Together they form a unique fingerprint.
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial. / Bruna, R.; Benedetti, F.; Boccomini, C.; Patti, C.; Barbui, A.M.; Pulsoni, A.; Musso, M.; Liberati, A.M.; Gini, G.; Castellino, C.; Rossini, F.; Ciceri, F.; Rota-Scalabrini, D.; Stelitano, C.; Di Raimondo, F.; Tucci, A.; Devizzi, L.; Zoli, V.; Zallio, F.; Narni, F.; Dondi, A.; Parvis, G.; Semenzato, G.; Lanza, F.; Perrone, T.; Angrilli, F.; Billio, A.; Gueli, A.; Mantoan, B.; Rambaldi, A.; Massimo Gianni, A.; Corradini, P.; Passera, R.; Ladetto, M.; Tarella, C.
In: Haematologica, Vol. 104, No. 11, 2019, p. 2241-2248.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial
AU - Bruna, R.
AU - Benedetti, F.
AU - Boccomini, C.
AU - Patti, C.
AU - Barbui, A.M.
AU - Pulsoni, A.
AU - Musso, M.
AU - Liberati, A.M.
AU - Gini, G.
AU - Castellino, C.
AU - Rossini, F.
AU - Ciceri, F.
AU - Rota-Scalabrini, D.
AU - Stelitano, C.
AU - Di Raimondo, F.
AU - Tucci, A.
AU - Devizzi, L.
AU - Zoli, V.
AU - Zallio, F.
AU - Narni, F.
AU - Dondi, A.
AU - Parvis, G.
AU - Semenzato, G.
AU - Lanza, F.
AU - Perrone, T.
AU - Angrilli, F.
AU - Billio, A.
AU - Gueli, A.
AU - Mantoan, B.
AU - Rambaldi, A.
AU - Massimo Gianni, A.
AU - Corradini, P.
AU - Passera, R.
AU - Ladetto, M.
AU - Tarella, C.
N1 - Export Date: 26 February 2020 CODEN: HAEMA Correspondence Address: Tarella, C.; Onco-Hematology Division, IEO, European Institute of Oncology IRCCSItaly; email: corrado.tarella@unimi.it Chemicals/CAS: immunoglobulin, 9007-83-4; lactate dehydrogenase, 9001-60-9; rituximab, 174722-31-7 Funding details: PRIN 2010-2011 Funding text 1: This work was supported in part by the Ministero Italiano Università e Ricerca (MIUR), Rome, Italy (grant PRIN 2010-2011, pr. N.: 2010B5B2NL), and by Banca del Piemonte (Torino, Italy). The initial clinical trial (March 2000 - May 2005) was made possible by Compagnia di San Paolo (Torino, Italy), Regione Piemonte (Torino, Italy), and by Roche (Milan, Italy), which provided free rituximab for all patients. We are indebted to GITMO (Gruppo Italiano Trapianto Midollo Osseo) and to IIL, now merged into FIL (Fondazione Italiana Linfomi) for their fundamental participation in the development and completion of the study. References: (2017) NCCN Clinical Practice Guidelines in Oncology. B-cell Lymphomas. Version 7.2017, , https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf, National Comprehensive Cancer Network. December 5, Accessed January 10, 2018; Dreyling, M., Ghielmini, M., Rule, S., Guidelines Committee Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) Ann Oncol, 27, pp. v83-v90. , on behalf of the ESMO; Corradini, P., Ladetto, M., Zallio, F., Longterm follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and au- tografting: Evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes (2004) J Clin Oncol, 22 (8), pp. 1460-1468; Lenz, G., Dreyling, M., Schiegnitz, E., Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission pro- longs progression-free survival in follicular lymphoma: Results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group (2004) Blood, 104 (9), pp. 2667-2674; Deconinck, E., Foussard, C., Milpied, N., High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: A randomized multicenter study by GOELAMS (2005) Blood, 105 (10), pp. 3817-3823; Hiddemann, W., Buske, C., Dreyling, M., Treatment strategies in follicular lymphomas: Current status and future perspectives (2005) J Clin Oncol, 23 (26), pp. 6394-6399; Sebban, C., Mounier, N., Brousse, N., Standard chemotherapy with interferon compared with CHOP followed by highdose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: The GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA) (2006) Blood, 108 (8), pp. 2540-2544; Brown, J.R., Feng, Y., Gribben, J.G., Longterm survival after autologous bone marrow transplantation for follicular lymphoma in first remission (2007) Biol Blood Marrow Transplant, 13 (9), pp. 1057-1065; Ladetto, M., De Marco, F., Benedetti, F., Prospective, multicenter randomized GITMO/IIL trial comparing intensive (RHDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: The superior disease control of R-HDS does not translate into an overall survival advantage (2008) Blood, 111 (8), pp. 4004-4013; Liu, Q., Fayad, L., Cabanillas, F., Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at the University of Texas M.D (2006) J Clin Oncol, 24 (10), pp. 1582-1589. , Anderson Cancer Center; Schulz, H., Bohlius, J.F., Trelle, S., Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis (2007) J Natl Cancer Inst, 99 (9), pp. 706-714; Tan, D., Horning, S.J., Hoppe, R.T., Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: The Stanford University experience (2013) Blood, 122 (6), pp. 981-987; Nabhan, C., Aschebrook-Kilfoy, B., Chiu, B.C., Kruczek, K., Smith, S.M., Evens, A.M., The impact of race, age, and sex in follicular lymphoma: A comprehensive SEER analysis across consecutive treatment eras (2014) Am J Hematol, 89 (6), pp. 633-638; Harris, N.L., Jaffe, E.S., Stein, H., A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group (1994) Blood, 84 (5), pp. 1361-1392; López-Guillermo, A., Montserrat, E., Bosch, F., Terol, M.J., Campo, E., Rozman, C., Applicability of the International Index for aggressive lymphomas to patients with lowgrade lymphoma (1994) J Clin Oncol, 12 (7), pp. 1343-1348; Federico, M., Vitolo, U., Zinzani, P.L., Prognosis of follicular lymphoma: A predictive model based on a retrospective analysis of 987 cases (2000) Blood, 95 (3), pp. 783-789; Rambaldi, A., Lazzari, M., Manzoni, C., Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma (2002) Blood, 99 (3), pp. 856-862; Tarella, C., Caracciolo, D., Corradini, P., Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft (2000) Leukemia, 14 (4), pp. 740-747; Ladetto, M., Corradini, P., Vallet, S., High rate of clinical and molecular remissions in follicular lymphoma patients receiving highdose sequential chemotherapy and autografting at diagnosis: A multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO) (2002) Blood, 100 (5), pp. 1559-1565; Cheson, B.D., Horning, S.J., Coiffier, B., Report of an international workshop to standardize re-sponse criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group (1999) J Clin Oncol, 17 (4), pp. 1244-1253; Corradini, P., Astolfi, M., Cherasco, C., Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with highdose chemotherapy and peripheral blood progenitor cell autografting (1997) Blood, 89 (2), pp. 724-731; Kaplan, E.L., Meier, P., Non parametric estimation from incomplete observations (1958) J Am Stat Assoc, 53 (282), pp. 457-481; Cheson, B.D., Pfistner, B., Juweid, M.E., International Harmonization Project on Lymphoma Revised response criteria for malignant lymphoma (2007) J Clin Oncol, 25 (5), pp. 579-586; Mantel, H., Haenszel, W., Statistical aspects of the analysis of data from retrospective studies of disease (1959) J Natl Cancer Inst, 22 (4), pp. 719-748; Cox, D.R., Regression models and life tables (1972) J Royal Stat Soc Series B, 34, pp. 187-220; Gray, R.S., A class of K-sample tests for comparing the cumulative incidence of a competing risk (1988) Ann Stat, 16 (3), pp. 1141-1154; R Foundation for Statistical Computing, Vienna-A, , http://www.R-project.org; Solal-Celigny, P., Roy, P., Follicular lymphoma international prognostic index (2004) Blood, 104 (5), pp. 1258-1265; Luminari, S., Ferrari, A., Manni, M., Longterm results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advancedstage symptomatic follicular lymphoma (2017) J Clin Oncol, 36 (7), pp. 689-696; Shadman, M., Li, H., Rimsza, L., Continued excellent outcomes in previously untreated patients with follicular lymphoma after treatment with CHOP plus rituximab or CHOP plus 131I-Tositumomab: Long-term follow-up of Phase III randomized study SWOG-S0016 (2018) J Clin Oncol, 36 (7), pp. 697-703; Sarkozy, C., Maurer, M.J., Link, B.K., Cause of death in follicular lymphoma in the first decade of the rituximab era: A pooled analysis of French and US cohorts (2019) J Clin Oncol, 37 (2), pp. 144-152; Salles, G., Seymour, J.F., Offner, F., Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial (2011) Lancet, 377 (9759), pp. 42-51; Rummel, M.J., Niederle, N., Maschmeyer, G., Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with in- dolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial (2013) Lancet, 381 (9873), pp. 1203-1210; Marcus, R., Davies, A., Ando, K., Obinutuzumab for the First-Line Treatment of Follicular Lymphoma (2017) N Engl J Med, 377 (14), pp. 1331-1344; Tarella, C., Passera, R., Magni, M., Risk Factors for the Development of Secondary Malignancy after High-Dose Chemotherapy and Autograft, with or without Rituximab: A 20-Year Retrospective Follow-Up Study in 1, 347 Patients with Lymphoma (2011) J Clin Oncol, 29 (7), pp. 814-824; Jiménez-Ubieto, A., Grande, C., Caballero, D., Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: A long-term follow-up analysis from the Spanish GELTAMO registry (2018) Bone Marrow Transplant, 53 (6), pp. 780-783. , on behalf of GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) Cooperative Study Group; Smith, S.M., Pitcher, B.N., Jung, S.H., Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: The Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials (2017) Lancet Haematol, 4 (4), pp. e176-e182; Leonard, J.P., Jung, S.H., Johnson, J., Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance) (2015) J Clin Oncol, 33 (31), pp. 3635-3640; Davids, M.S., Roberts, A.W., Seymour, J.F., Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma (2017) J Clin Oncol, 35 (8), pp. 826-833; Tarella, C., Gueli, A., Delaini, F., Rate of Primary Refractory Disease in B and T-Cell Non-Hodgkin's Lymphoma: Correlation with Long-Term Survival (2014) PLoS One, 9 (9), p. e106745; Casulo, C., Byrtek, M., Dawson, K.L., Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: An analysis from the National LymphoCare Study (2015) J Clin Oncol, 33 (23), pp. 2516-2522; Shi, Q., Flowers, C.R., Hiddemann, W., Thirty-month completer esponse as a surrogate end point in first-line follicular lymphoma Therapy: An individual patient-level analysis of multiple randomized trials (2017) J Clin Oncol, 35 (5), pp. 552-560; Sorigue, M., Mercadal, S., Alonso, S., Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome (2017) Hematol Oncol, 35 (4), pp. 520-527; Provencio, M., Royuela, A., Torrente, M., Prognostic value of eventfree survival at 12 and 24 months and longterm mortality for non-Hodgkin follicular lymphoma patients: A study report from the Spanish Lymphoma Oncology Group (2017) Cancer, 123 (19), pp. 3709-3716. , on behalf of the Spanish Lymphoma Oncology Group; Gribben, J.G., Freedman, A.S., Neuberg, D., Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma (1991) N Engl J Med, 325 (22), pp. 1525-1533; Ladetto, M., Lobetti-Bodoni, C., Mantoan, B., Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program (2013) Blood, 122 (23), pp. 3759-3766. , onbehalf of Fondazione Italiana Linfomi; Gritti, G., Pavoni, C., Rambaldi, A., Is there a role for minimal residual disease monitoring in follicular lymphoma in the chemo-immunotherapy era? (2017) Mediterr J Hematol Infect Dis, 9 (1), p. e2017010; Casulo, C., Nastoupil, L., Fowler, N.H., Friedberg, J.W., Flowers, C.R., Unmet needs in the first-line treatment of follicular lymphoma (2017) Ann Oncol, 28 (9), pp. 2094-2106
PY - 2019
Y1 - 2019
N2 - Aprospective trial conducted in the period 2000-2005 showed no survival advantage for high-dose chemotherapy with rituximab and autograft (RHDS) versus conventional chemotherapy with rituximab (CHOP-R) as firstline therapy in 134 high-risk follicular lymphoma patients aged
AB - Aprospective trial conducted in the period 2000-2005 showed no survival advantage for high-dose chemotherapy with rituximab and autograft (RHDS) versus conventional chemotherapy with rituximab (CHOP-R) as firstline therapy in 134 high-risk follicular lymphoma patients aged
KW - cyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine
KW - immunoglobulin
KW - lactate dehydrogenase
KW - rituximab
KW - acute leukemia
KW - adult
KW - anaphylaxis
KW - Article
KW - autograft
KW - autologous hematopoietic stem cell transplantation
KW - cancer growth
KW - cancer immunotherapy
KW - cancer staging
KW - cancer survival
KW - controlled study
KW - disease exacerbation
KW - disease free survival
KW - female
KW - follicular lymphoma
KW - Follicular Lymphoma International Prognostic Index
KW - follow up
KW - human
KW - male
KW - middle aged
KW - minimal residual disease
KW - multicenter study
KW - myelodysplastic syndrome
KW - overall survival
KW - polymerase chain reaction
KW - prospective study
KW - randomized controlled trial
KW - remission
KW - sudden death
U2 - 10.3324/haematol.2018.209932
DO - 10.3324/haematol.2018.209932
M3 - Article
VL - 104
SP - 2241
EP - 2248
JO - Haematologica
JF - Haematologica
SN - 0390-6078
IS - 11
ER -